印迪维奥 INDV

Ryan was appointed Chief Financial Officer and Executive Director in November 2020, having served as Interim Chief Financial Officer from June to November 2020. He has a wealth of financial and pharmaceutical industry knowledge and experience across multiple disciplines covering strategy, finance, information technology, commercial and supply, which allows him to bring a valuable perspective to the Board. › Indivior SVP, Global Finance & Commercial Operations › Indivior VP, US Finance › Altria Corporation (formerly Philip Morris) Senior Manager Financial Planning & Analysis › Honeywell International Corporate Finance Other current appointments None.

Mark has over 30 years of experience in biotech and pharmaceuticals, including senior roles in a range of commercial functions including marketing, sales, economic affairs, managed care and finance. Mark most recently served as Senior Vice President and Chief Commercial Officer at Alkermes plc, where he was responsible for building sales of Vivitrol from $40m to $300m. › Flexion Therapeutics: Non-Executive Director (2016-2021) › Tengion, Inc.: Chief Commercial Officer (2008-2012) › EIP Pharma Inc.: Senior Commercial Advisor Other current appointments None

Barbara Ryan as an Independent Non-Executive Director of the Company with effect from June 1, 2022. Barbara was a Wall Street sell-side research analyst covering the US Large Cap Pharmaceutical Industry for more than 30 years before founding Barbara Ryan Advisors, a capital markets and communications firm, in 2012. Barbara has deep experience in equity and debt financings, M&A, valuation, SEC reporting, financial analysis and corporate strategy across a broad range of life sciences companies. Barbara is also the Founder of Fabulous Pharma Females, a non-profit organization whose mission is to advance women in the biopharma industry. Barbara is a Senior Advisor at EY and is currently a Non-Executive Director of INVO Bioscience

Keith Humphreys has been appointed to the board as non-executive director with effet from 09th Nov 2023. Dr. Humphreys is an Esther Ting Memorial Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University. He was previously a Senior Policy Advisor in the White House Office of National Drug Control Policy in the Obama Administration and is an Honorary Professor of Psychiatry at the Institute of Psychiatry, King's College, London. Dr. Humphreys was awarded an OBE in September 2022 for his services to science and policy on addiction.

Juliet has over 30 years of finance, banking and board experience with significant focus in the healthcare sector. Juliet is a proven FTSE 250 audit chair and a former investment banker who has spent her career advising pharmaceutical and biotech companies. › Juliet played a leading role in setting up Code Securities, an investment banking firm focusing on the healthcare sector, which was later acquired by Nomura (becoming Nomura Code). At Nomura Code, Juliet was a member of the Board and head of corporate finance. As Managing Director, she worked on over 50 transactions. › Stifel: headed up the life sciences where she advised CEOs and CFOs in the healthcare sector › Vectura plc: Non-Executive Director › GI Dynamics: Non-Executive Director › Chartered Accountant holding an ACA from ICAEW › BSc in Economics from the University of Bristol Other current appointments › Novacyt: Non-Executive Director › OrganOx: Non-Executive Director. Juliet Thompson, non-executive director, will be appointed as Senior Independent director with effect from 01st October 2023.

Jo is a healthcare industry veteran with 25 years’ healthcare management experience gained in Europe, the US and Asia. Much of her career has been in pharmaceuticals at GlaxoSmithKline where, amongst other roles, she headed the US vaccines business and Asia Pacific Pharmaceuticals business and led a program to modernize the commercial model. › BMI Healthcare: Chief Operating Officer › Frimley Park NHS Foundation Trust: Non-Executive Director › Cello Health PLC: Non-Executive Director › Duke NUS Medical School in Singapore: Non-Executive Director Other current appointments › Circassia Group plc: Non-Executive Director › Alliance Pharma plc: Non-Executive Director › Recordati S.p.A.: Non-Executive Director

Peter has over 30 years of experience in the pharmaceutical and biotechnology industries including a 23-year career at GlaxoSmithKline where he held numerous senior operational and strategic roles. His background provides international experience and a deep commercial understanding of sustained delivery coupled with investment appraisal and contracting. The Board values his experience in understanding the risks and opportunities present in these industries. › Sosei Group Corporation: Chief Executive Officer (2010-2018) › Syngene International: Chief Executive Officer (2010-2016) Other current appointments › ILC Therapeutics Limited: Chairman › Apterna Limited: Non-Executive Director › MiNA Therapeutics Limited: Chief Business Officer (part-time role)

David Wheadon will be appointed to the board Independent as non-executive director with effect from 01 June 2024. Dr. Wheadon previously served as senior vice president of global regulatory affairs, patient safety, and quality assurance at AstraZeneca Plc from December 2014 to July 2019. Prior to that, he was executive vice president, research and advocacy at Juvenile Diabetes Research Foundation International Inc., from May 2013 to December 2014, and senior vice president, scientific and regulatory affairs at Pharmaceutical Research and Manufacturers of America (PhRMA), from January 2009 to May 2013. Dr. Wheadon served as vice president, global pharmaceutical regulatory and medical science, and group vice president, global pharmaceutical regulatory affairs at Abbott Laboratories from 2005 to 2009. Prior to Abbott Laboratories, Dr. Wheadon held senior regulatory and clinical development leadership positions at GlaxoSmithKline Plc and Eli Lilly and Company. Dr. Wheadon received his M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts. Dr. Wheadon is a Non-executive Independent Director of Sotera Health Company (Nasdaq: SHC), Vaxart, Inc (Nasdaq: VXRT), and ConnectiveRx. He also serves as a member of the Board of Trustees of Mount Sinai Health System. Prior to its recent acquisition by Bristol-Myers Squibb Company, Dr. Wheadon served as a Non-executive Independent Director of Karuna Therapeutics, Inc. Dr. David Wheadon has been appointed as Chair of the Board with effect from 28 January 2025.

Robert Schriesheim has been appointed to the board as independent non-executive director with effect from 17 Dec 2024. Robert Schriesheim serves as Chairman of Truax Partners LLC and has extensive experience as a board member of public and private companies typically undergoing transformations while partnering with boards and institutional investors. In addition, he serves as an Adjunct Associate Professor of Finance with a focus on corporate governance at The University of Chicago Booth School of Business. He previously served as CFO of Sears Holdings, Hewitt Associates and Lawson Software and, earlier, held executive roles at seed venture firm ARCH Development Partners, LLC, Global TeleSystems, SBC Equity Partners, Ameritech, AC Nielsen and Brooke Group Ltd. Mr. Schriesheim has served as a director of Skyworks Solutions, Inc. since 2006 and Houlihan Lokey since 2015 where he is the Lead Independent Director. He previously served on a number of public boards including Frontier Communications (as chairman of the Finance Committee overseeing its strategic redirection and Chapter 11 proceedings), NII Holdings, Forest City Reality Trust, Lawson Software, Co-Chairman of MSC Software and Dobson Communications. Mr. Schriesheim earned an AB in Chemistry from Princeton University and an MBA from the University of Chicago Booth School of Business.

Joe Ciaffoni has been appointe to the board as independent non-executive director with effect from 17 Dec 2024. Joe Ciaffoni previously served as President and CEO of Collegium Pharmaceutical. Given his prior experience at not only Collegium, but also Endo International (President of U.S. Branded Pharmaceuticals), Biogen (SVP, Global Specialty Medicines Group; U.S. Commercial) and Shionogi Inc. (COO), Mr. Ciaffoni has a demonstrated track record of launching successful products, optimizing commercial operations, and enhancing patient access to important therapies. He earned his MBA and BA at Rutgers University. Joe Ciaffoni, independent non-executive director, will be appointed as Chief Executive Officer with effect AGM in may 2025

Over 20 years of experience as a Company Secretary and Chartered Governance Professional › Fellow of the Chartered Governance Institute › Kingfisher plc: Company Secretary (2012-2015) › Senior Company Secretarial positions at Burberry Group plc and ICAP plc Other current appointments None

Stuart Kingsley has been appointed to the board as non-executive director with effect from 01st July 2025. Mr. Kingsley currently serves as CEO and Director of Stablix, Inc., a biotechnology company pioneering deubiquitination therapeutics as novel modality. Prior to joining Stablix, Mr. Kingsley was President and CEO of Scholar Rock (Nasdaq: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases driven by protein growth factors. Previously, he led TARIS Bio as President and CEO, guiding the company through its acquisition by Janssen Pharmaceuticals in 2019. Earlier in his career, Mr. Kingsley held a series of senior leadership roles, including President and Chief Operating Officer at The Medicines Company (Nasdaq: MDCO) and Executive Vice President of Global Commercial Operations at Biogen (Nasdaq: BIIB), where he oversaw the launch and growth of multiple therapies in neurology and hemophilia. Prior to this, he held numerous senior general management roles in devices and diagnostics and was a partner at McKinsey & Company. Mr. Kingsley graduated magna cum laude from Dartmouth College and received an M.B.A. from Harvard Business School. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment.

Daniel A.Ninivaggi has appointed as independent non-executive officer to the board with effect from 03 February 2025. Daniel A. Ninivaggi is currently Chairman of Garrett Motion Inc. (NASDAQ:GTX), a Switzerland-based supplier of turbochargers and other products designed to improve energy efficiency and reduce emissions in vehicles and industrial equipment. From August 2021 until March 2024, Mr. Ninivaggi formerly served as the Chief Executive Officer and subsequently the Executive Chairman of Lordstown Motors Corp, an electric vehicle automaker. Prior to that, Mr. Ninivaggi served as the President and Chief Executive Officer of Icahn Enterprises L.P. (IEP) (NASDAQ:IEP), the principal investment vehicle of Carl Icahn, between 2010 and 2014; Co-Chief Executive Officer of Federal-Mogul Holdings Corp. (a public-company subsidiary of IEP now part of Apollo Global Management) from 2014 until 2017; and Chief Executive Officer of Icahn Automotive Group, LLC and a Managing Director of IEP from 2017 until 2019. Prior to joining IEP, Mr. Ninivaggi spent six years at Lear Corporation (NYSE:LEA), holding various senior executive positions. Mr. Ninivaggi has served as a director of numerous public and private companies, including Garrett Motion Inc., Lordstown Motors Corp., Hertz Global Holdings Inc., Navistar International Corporation, Icahn Enterprises G.P. Inc. (the general partner of Icahn Enterprises), CVR Energy Inc., LLC, XO Holdings, Tropicana Entertainment Inc., Motorola Mobility Holdings Inc., and CIT Group, Inc. Mr. Ninivaggi began his career at Skadden, Arps, Slate, Meagher & Flom LLP before joining Winston & Strawn LLP, where he became a partner specializing in mergers & acquisitions, financing transactions and corporate governance. . He holds a Bachelor of Arts degree from Columbia University, an MBA from the University of Chicago Graduate School of Business, and a law degree (Juris Doctor) (with distinction) from Stanford University School of Law.